Potential Price Increase for Alpine Immune Sciences Inc (ALPN) After Recent Insider Activity

In a filing, Alpine Immune Sciences Inc revealed its insider Rickey James Paul unloaded Company’s shares for reported $2.75 million on Jan 26. In the deal valued at $23.32 per share,117,764 shares were sold. As a result of this transaction, Rickey James Paul now holds 0 shares worth roughly $0.0.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Then, Rickey James Paul sold 236 shares, generating $5,192 in total proceeds. Upon selling the shares at $22.00, the insider now owns 0 shares.

Before that, Thompson Peter A. sold 1,364,849 shares. Alpine Immune Sciences Inc shares valued at $25,049,034 were divested by the Director at a price of $18.35 per share. As a result of the transaction, Thompson Peter A. now holds 264,315 shares, worth roughly $6.9 million.

Berenberg initiated its Alpine Immune Sciences Inc [ALPN] rating to a Buy in a research note published On Monday, October 18, 2023; the price target was $18.

Price Performance Review of ALPN

On Monday, Alpine Immune Sciences Inc [NASDAQ:ALPN] saw its stock jump 3.90% to $26.10. Over the last five days, the stock has gained 31.42%. Alpine Immune Sciences Inc shares have risen nearly 36.94% since the year began. Nevertheless, the stocks have risen 232.48% over the past one year. While a 52-week high of $25.34 was reached on 01/29/24, a 52-week low of $6.39 was recorded on 01/05/24. SMA at 50 days reached $18.04, while 200 days put it at $12.70. A total of 2.27 million shares were traded, compared to the trading of 2.94 million shares in the previous session.

Levels Of Support And Resistance For ALPN Stock

The 24-hour chart illustrates a support level at 25.03, which if violated will result in even more drops to 23.96. On the upside, there is a resistance level at 26.70. A further resistance level may holdings at 27.30. The Relative Strength Index (RSI) on the 14-day chart is 76.37, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.56, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 1.69%. Stochastics %K at 96.64% indicates the stock is a selling.

How much short interest is there in Alpine Immune Sciences Inc?

A steep rise in short interest was recorded in Alpine Immune Sciences Inc stocks on Jan 11, 2024, dropping by -0.59 million shares to a total of 2.41 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2023 was 3.0 million shares. There was a decline of -24.48%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 7.34% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.93.

Alpine Immune Sciences Inc [ALPN] – Who Are The Largest Shareholders?

In filings from RA Capital Management LP, it is revealed that the company now owns 4,691,178 shares, or roughly 8.09% of the outstanding ALPN shares. Additionally, Great Point Partners LLC decreased -8.47% of its stake after which the total value it holdings stand at $58,678,745, while Cormorant Asset Management LP added 50.00% of its stake to hold $54.32 million in the firm. Over the last quarter, Paradigm BioCapital Advisors LP sold -2,218 shares of Alpine Immune Sciences Inc, while Lynx1 Capital Management LP sold -265,858 shares. At present, BlackRock Fund Advisors is holding 2,155,321 shares valued at $41.08 million. The Vanguard Group, Inc. owned 1,412,585 shares of the company at the time of its most recent 13F filing, worth $26.92 million.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular